Recombinant Newcastle Disease Virus Expressing P53 Demonstrates Promising Antitumor Efficiency in Hepatoma Model.
Ying An,Tianyan Liu,Jinjiao He,Hongsong Wu,Rui Chen,Yunye Liu,Yunzhou Wu,Yin Bai,Xiaochen Guo,Qi Zheng,Chang Liu,Jiechao Yin,Deshan Li,Guiping Ren
DOI: https://doi.org/10.1186/s12929-016-0273-0
2016-01-01
Journal of Biomedical Science
Abstract:BACKGROUND:Numerous studies have demonstrated that the NDV-mediated gene therapy is a promising new approach for treatment of cancers. P53 plays a vital role in tumor suppression and surveillance. Therefore, we hypothesize that a recombinant NDV expressing P53 would be an ideal agent for the hepatoma therapy.RESULTS:In the essay, the human P53 gene was incorporated into the genome of a lentogenic strain (named rNDV-P53), which did not affect viral replication kinetics and magnitude in HepG2 cells. Compared to the vehicle virus, rNDV-P53 increased cell growth suppressor ratio and early apoptosis by 2 folds, and decreased the mitochondrial membrane potential in HepG2 cells. In vivo studies, treatment with rNDV-P53 reduced tumor volume of tumor-bearing mice by more than 4 folds, tumor weight by more than 5 folds comparing with rNDV. The 120-day survival rate of rNDV-P53-treated mice was 75 %, survival rate of rNDV-treated mice was 12.5 %. TUNEL analysis showed a significant increase in the apoptosis rate in the tumor tissues of rNDV-P53-treated mice than that of rNDV-treated mice. Moreover, serum chemistries revealed an insignificant change of blood urea nitrogen (BUN), creatinine levels, alanine aminotransferase (ALT) and aspartate transaminase (AST) in rNDV-P53-treated group compared to normal mice, suggesting treatment with the recombinant virus was not toxic.CONCLUSION:rNDV-P53 is a potent candidate for carcinoma therapy especially for hepatocarcinoma.